Dutasteride for low-grade bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if the drug dutasteride can help people with a slow-growing type of bladder cancer that hasn't spread into the muscle wall. It may be an option for those not receiving other standard treatments like BCG therapy or chemotherapy directly into the bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with low-grade bladder cancer that hasn't spread to the bladder muscle.
- Your urologist has decided you do not need an induction course of BCG or chemotherapy into the bladder.
- If you are male and have a partner who could become pregnant, you agree to use two forms of birth control during the study and for 6 months after stopping the drug.
- You have not used dutasteride or similar medications (like finasteride) in the last 2 years.
- You are not pregnant or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether putting two chemotherapy drugs (gemcitabine and docetaxel) directly into the bladder can treat low-grade bladder cancer that is at intermediate risk. The goal is to see if this approach can help people avoid more invasive treatments.
This early-phase trial tests durvalumab given with an experimental bladder cancer vaccine to help stop or slow high-risk bladder cancer that did not respond to or cannot be treated with BCG. It also evaluates safety and how well the treatment works in this setting.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This study compares two approaches for people with early-stage bladder cancer that has a low chance of coming back: either careful monitoring without immediate treatment, or receiving chemotherapy directly into the bladder to lower the risk of recurrence. It aims to see if monitoring alone is as good as chemotherapy for those with a low risk detected by a urine test.
This trial tests a new, precise way to use chemotherapy to remove low-risk, non-muscle-invasive bladder tumors before surgery. It may be an option for people with small, slow-growing tumors that haven't spread into the bladder muscle.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.